Previous Close | 8.14 |
Open | 7.86 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 7.86 - 7.86 |
52 Week Range | 3.22 - 10.00 |
Volume | |
Avg. Volume | 179 |
Market Cap | 505.782M |
Beta (5Y Monthly) | 2.21 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Provention Bio, Inc. ( NASDAQ:PRVB ) is possibly approaching a major achievement in its business, so we would like to...
A look at the shareholders of Provention Bio, Inc. ( NASDAQ:PRVB ) can tell us which group is most powerful. The group...
Shares of Provention Bio (NASDAQ: PRVB) rose 30.3% in November, according to data from S&P Global Intelligence. The pharmaceutical company closed out October at $6.94 and opened November at $7. The move up can be directly tied to the approval of Provention therapy Tzield (teplizumab-mzwv) by the Food and Drug Administration (FDA) on Nov. 17.